Roche Plans $50 Billion Investment, Creating 12,000 Jobs Across US

Roche has announced a $50 billion investment plan over the next five years to expand its U.S. presence, enhancing its existing infrastructure of 13 manufacturing and 15 research and development sites. The investment will fund new manufacturing facilities—including a 900,000-square-foot center for next-generation weight loss drugs and a continuous glucose monitoring plant in Indiana—as well as a gene therapy facility in Pennsylvania and an AI-focused R&D center in Massachusetts. Roche will also upgrade and expand its pharmaceutical and diagnostics R&D centers in Arizona, Indiana, and California, and enhance manufacturing and distribution capabilities in Kentucky, Indiana, New Jersey, Oregon, and California. The initiative is expected to create over 12,000 jobs, including 6,500 construction roles and 1,000 positions at new facilities. This move comes amid ongoing discussions about potential U.S. drug tariffs and reflects Roche's commitment to innovation, job creation, and increasing exports of medicines from the U.S. Roche's CEO highlighted the company's 110-year legacy in the U.S. as a driver for jobs and innovation.